NSD2 and acute lymphoblastic leukemia: The NSD2 EK mutation results in increased methyltransferase activity leading to a global increase in H3K36me2 levels (active mark) as well as the concomitant inhibition of EZH2-mediated H3K27me3 levels (repressive mark) in pediatric ALL [6, 7].